Cytomegalovirus DNAemia and disease: Incidence, natural history and management in settings other than allogeneic stem cell transplantation

Haematologica

Volumn 90, Issue 12, 2005, Pages 1672-1679

  Ng, Ashley P ^a,b,d   Worth, Leon ^d,e   Chen, Luke ^c   Seymour, John F ^a,b   Prince, H Miles ^a,b   Slavin, Monica ^d,e   Thursky, Karin ^d,e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Alfred Hospital ^*  (Australia)

^c ALFRED HOSPITAL   (Australia)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

CMV disease; CMV DNAemia; Cytomegalovirus; Ganciclovir

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ANTINEOPLASTIC AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; FLUDARABINE; GANCICLOVIR; RITUXIMAB; VALACICLOVIR; VIRUS DNA;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL DISEASE; HEMATOLOGIC MALIGNANCY; HISTORY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; POLYMERASE CHAIN REACTION; REVIEW; SCREENING; VIRUS DETECTION; VIRUS REACTIVATION; VIRUS TITRATION;

ACYCLOVIR; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; COHORT STUDIES; CYCLOPHOSPHAMIDE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DEXAMETHASONE; DIPHTHERIA TOXIN; DNA, VIRAL; DOXORUBICIN; FEMALE; FEVER; FOLLOW-UP STUDIES; GANCICLOVIR; HEMATOLOGIC NEOPLASMS; HUMANS; INTERLEUKIN-2; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POLYMERASE CHAIN REACTION; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS; VALINE; VIDARABINE; VINCRISTINE; VIREMIA; VIRUS ACTIVATION;

EID: 29144515396     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Hakki M, Boeckh M. Management of CMV infection in hematopoietic stem cell transplantation recipients. In: Wingard J, Bowden R, eds. Management of infection in oncology patients. 1st ed. Seattle: Martin Dunitz; 2003. p. 249-67.
2. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986;153:478-88.
3. Ljungman P, Reusser P, de la Camara R, Einsele H, Engelhard D, Ribaud P, et al. Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant 2004;33:1075-81.
4. Meijer E, Boland GJ, Verdonck LE Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clin Microbiol Rev 2003; 16:647-57.
5. Zaia JA. Prevention and management of CMV-related problems after hematopoietic stem cell transplantation. Bone Marrow Transplant 2002;29:633-8.
6. Qamruddin AO, Oppenheim BA, Guiver M, Mutton KJ, Chopra R. Screening for cytomegalovirus (CMV) infection in allogeneic bone marrow transplantation using a quantitative whole blood polymerase chain reaction (PCR) method: analysis of potential risk factors for CMv infection. Bone Marrow Transplant 2001;27:301-6.
7. Schulenburg A, Watkins-Riedel T, Greinix HT, Rabitsch W, Loidolt H, Keil F, et al. CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCK. Bone Marrow Transplant 2001;28:765-8.
8. Boeckh M, Boivin G. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin Microbiol Rev 1998;11:533-54.
9. Gozlan J, Laporte JP, Lesage S, Labopin M, Naiman A, Gorin NC, et al. Monitoring or cytomegalovirus infection and disease in bone marrow recipients by reverse transcription-PCR and comparison with PCR and blood and urine cultures. J Clin Microbiol 1996;34:2085-8.
10. Ljungman P, Aschan J, Lewensohn-Fuchs I, Carlens S, Larsson K, Lonnqvist B, et al. Results of different strategies for reducing cytomegalovirus- associated mortality in allogeneic stem cell transplant recipients. Transplantation 1998; 66:1330-4.
11. Nguyen Q, Estey E, Raad I, Rolston K, Kantarjian H, Jacobson K, et al. Cytomegalovirus pneumonia in adults with leukemia: an emerging problem. Clin Infect Dis 2001;32:539-45.
12. Bilgrami S, Aslanzadeh J, Feingold JM, Bona RD, Clive J, Dorsky D, et al. Cytomegalovirus viremia, viruria and disease after autologous peripheral blood stem cell transplantation: no need for surveillance. Bone Marrow Transplant 1999;24:69-73.
13. Offidani M, Corvatta L, Olivieri A, Rupoli S, Frayfer J, Mele A, et al. Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF. Bone Marrow Transplant 1999;24:1079-87.
14. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-61.
15. Holmberg LA, Boeckh M, Hooper H, Leisenring W, Rowley S, Heimfeld S, et al. Increasea incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood 1999;94:4029-35.
16. Druce J, Catton M, Chibo D, Minerds K, Tyssen D, Kostecki R, et al. Utility of a multiplex PCR assay for detecting herpesvirus DNA in clinical samples. J Clin Microbiol 2002;40:1728-32.
17. Eisen D, Essell J, Broun ER, Sigmund D, DeVoe M. Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy. Bone Marrow Transplant 2003;31:51-5.
18. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002;34:1094-7.
19. Liesnard C, De Wit L, Motte S, Brancart F, Content J. Rapid diagnosis of cytomegalovirus lung infection by DNA amplification in bronchoalveolar lavages. Mol Cell Probes 1994;8:273-83.
20. Wijermans PW, Gerrits WB, Haak HL. Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol 1993;50:292-6.
21. Byrd JC, Hargis JB, Kester KE, Hospenthal DR, Knutson SW, Diehl LF. Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role For Pneumocystis carinii pneumonia prophylaxis. Am J Hematol 1995;49:135-42.
22. Bergmann L, Fenchel K, Jahn B, Mitrou PS, Hoelzer D. Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Ann Oncol 1993;4:371-5.
23. Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002;20:3891-7.
24. Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003;101:3413-5.
25. Lundin J, Hagberg H, Repp R, Cavallin-Stahl E, Freden S, Juliusson G, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003;101:4267-72.
26. Fassas AB, Bolanos-Meade J, Buddharaju LN, Rapoport A, Cottier-Fox M, Chen T, et al. Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma. Br J Haematol 2001;112:237-41.
27. Hebart H, Schroder A, Loffler J, Klingebiel T, Martin H, Wassmann B, et al. Cytomegalovirus monitoring by polymerase chain reaction of whole blood samples from patients undergoing autologous bone marrow or peripheral blood progenitor cell transplantation. J Infect Dis 1997;175:1490-3.
28. Peggs KS, Mackinnon S. Cytomegalovirus infection and disease after autologous peripheral blood stem cell transplantation. Br J Haematol 2001;115: 1032-3.
29. Peggs KS, Ings SJ, Kottaridis PD, Yong K, Williams CD, Goldstone AH, et al. Cytomegalovirus infection and disease after autologous CD34-selected peripheral blood stem cell transplantation for multiple myeloma: no evidence of increased incidence based on polymerase-chain-reaction monitoring. Blood 2000;96:369-70.
30. Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 2004;4:725-38.
31. Hummel M, Abecassis MM. A model for reactivation of CMV from latency. J Clin Virol 2002-25 Suppl 2:5123-36.
32. Reusser P, Cathomas G, Attenhofer R, Tamm M, Thiel G. Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load. J Infect Dis 1999; 180:247-53.
33. Gamadia LE, Remmerswaal EB, Weel JF, Bemelman F, van Lier RA, Ten Berge IJ. Primary immune responses to human CMV: a critical role for IFN-α-producing CD4+ T cells in protection against CMV disease. Blood 2003;101: 2686-92.
34. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994;83: 1971-9.
35. Quinnan GV Jr, Kirmani N, Rook AH, Manischewitz JF, Jackson L, Moreschi G, et al. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med 1982;307:7-13.
36. Guillaume T, Rubinstein DB, Symann M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 1998;92:1471-90.
37. Steingrimsdottir H, Gruber A, Björkholm M, Svensson A, Hansson M. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications. Haematologica 2000;85:832-8.
38. Reusser P, Attenhofer R, Hebart H, Helg C, Chapuis B, Einsele H. Cytomegalovirus-specific T-cell immunity in recipients of autologous peripheral blood stem cell or bone marrow transplants. Blood 1997;89:3873-9.
39. Buggins AG, Mufti GJ, Salisbury J, Codd J, Westwood N, Arno M, et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood 2002;100:1715-20.
40. osari A, Montillo M, Morra E. Infectious toxicity using alemtuzumab. Haematologica 2004;89:1414-9.
41. Konoplev S, Champlin RE, Giralt S, Ueno NT, Khouri I, Raad I, et al. Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients. Bone Marrow Transplant 2001;27:877-81.
42. Reusser P, Fisher LD, Buckner CD, Thomas ED, Meyers JD. Cytomegalovirus infection after autologous bone marrow transplantation: occurrence of cytomegalovirus disease and effect on engraftment. Blood 1990;75:1888-94.
43. Ljungman P, Biron P, Bosi A, Cahn JY, Goldstone AH, Gorin NC, et al. Cytomegalovirus interstitial pneumonia in autologous bone marrow transplant recipients. Infectious Disease Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1994;13:209-12.
44. Wingard JR, Sostrin MB, Vriesendorp HM, Mellits ED, Santos GW, Fuller DJ, et al. Interstitial pneumonias following autologous bone marrow transplantation. Transplantation 1988;46:61-5.
45. Suzan F, Ammor M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 2001;345:1000.
46. Laurenti L, Piccioni P, Cattani P, Cingolani A, Efremov D, Chiusolo P, et al. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica 2004;89:1248-52.
47. Keating M, Coutre S, Rai K, Osterborg A, Faderl S, Kennedy B, et al. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma 2004;4:220-7.
48. Thursky KA, Worth LJ, Seymour JF, Prince HM, Slavin MA. Spectrum of infection, risks and recommendations for prophylaxis and screening among patients with Lymphoproliferative disorders treated with alemtuzumab. Br J Haematol 2005; (in press).
49. Appelbaum FR. The influence of total dose, fractionation, dose rate, and distribution of total body irradiation on bone marrow transplantation. Semin Oncol 1993;20 Suppl 4:3-10.
50. Lundin J, Kimby E, Bjorkholm M, Broliden PA, Celsing F, Hjalmar V, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100:768-73.
51. Oscier D, Fegan C, Hillmen P, Illidge T, Johnson S, Maguire P, et al. Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol 2004;125:294-317.
52. Schaade L, Kockelkorn P, Ritter K, Kleines M. Detection of cytomegalovirus DNA in human specimens by LightCycler PCR. J Clin Microbiol 2000; 38:4006-9.
53. Ikewaki J, Ohtsuka E, Kawano R, Ogata M, Kikuchi H, Nasu M. Real-time PCR assay compared to nested PCR and antigenemia assays for detecting cytomegalovirus reactivation in adult T-cell leukemia-lymphoma patients. J Clin Microbiol 2003;41:4382-7.
54. Boeckh M, Huang M, Ferrenberg J, Stevens-Ayers T, Stensland L, Nichols WG, et al. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol 2004;42:1142-8.
55. Reusser P. Oral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts. Expert Opin Investig Drugs 2001;10:1745-53.
56. Gratama JW, Cornelissen JJ. Clinical utility of tetramer-based immune monitoring in allogeneic stem cell transplantation. BioDrugs 2003;17:325-38.